2. Search Result
Search Result
Results for "

Immunosuppressed C57BL/6 mice

" in MedChemExpress (MCE) Product Catalog:

2637

Inhibitors & Agonists

1

Screening Libraries

18

Fluorescent Dye

29

Biochemical Assay Reagents

193

Peptides

1

MCE Kits

94

Inhibitory Antibodies

417

Natural
Products

78

Isotope-Labeled Compounds

1

Antibodies

12

Click Chemistry

35

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0538
    Xylitol

    Xylite

    		 Autophagy Endogenous Metabolite Bacterial Atg7 Atg8/LC3 Metabolic Disease Cancer
    Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol
  • HY-160025
    IDO antagonist-1

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-169953
    BT-Amide

    		Pyk2 Metabolic Disease
    BT-Amide is the orally active inhibitor for Pyk2 kinase with IC50 of 44.69 nM. BT-Amide prevents glucocorticoid-induced bone loss, exhibits bone protective activity in C57BL/6 mouse .
    BT-Amide
  • HY-157429
    25N-N1-Nap

    		5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice .
    25N-N1-Nap
  • HY-128435
    2,4'-Dihydroxybenzophenone-1

    		Estrogen Receptor/ERR Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-144743
    ATX inhibitor 12

    		Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-170362
    cGAS-IN-4

    		Cyclic GMP-AMP Synthase Inflammation/Immunology
    cGAS-IN-4 (Compound 36) is an orally active inhibitor for cyclic GMP-AMP synthase (cGAS) with IC50 of 32 nM and 5.8 nM for h-cGAS and m-cGAS. cGAS-IN-4 inhibits the cGAMP in THP-1 cell with an IC50 of 60 nM, which improves the cellular potency. cGAS-IN-4 exhibits anti-inflammatory efficacy in Concanavalin A (HY-P2149)-induced acute liver injury in mouse models . orally active, THP-1, C57Bl/6 mouse, orally active
    cGAS-IN-4
  • HY-172930
    PVTX-405

    		Molecular Glues IKZF Family Potassium Channel Inflammation/Immunology Cancer
    PVTX-405 is a selective and oral active IKZF2 molecular glue degrader with a DC50  of  0.7 nM and a Dmax of 91%. PVTX-405 enhances degradation efficiency, significantly reduces off-target degradation, and alleviates hERG inhibition with IC50 of 48 µM. PVTX-405 significantly inhibits the growth of MC38 tumors, with greater synergistic anti-cancer efficacy in combination with immune checkpoint therapies (ICTs) (anti-PD1 or anti-LAG3) in the MC38 mouse tumor xenograft model using Crbn 391V C57BL/6 mice .
    PVTX-405
  • HY-168081
    PD-1/PD-L1-IN-52

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .
    PD-1/PD-L1-IN-52
  • HY-162972
    PROTAC PD-L1 degrader-2

    		PROTACs PD-1/PD-L1 Cancer
    PROTAC PD-L1 degrader-2 (Compound 9i) is a PROTAC degrader for PD-L1, that inhibits PD-L1 with an IC50 of 197.4 nM and exhibits an affinity with PD-L1 with a Kd of 301 nM. PROTAC PD-L1 degrader-2 promotes the internalization of PD-L1 on the cell membrane, and induces PD-L1 degradation via the synergistic effect of the proteasome and lysosomal pathways. PROTAC PD-L1 degrader-2 can activate the immune system, and exhibits antitumor efficacy in MC38 C57BL/6 mouse model .
    PROTAC PD-L1 degrader-2
  • HY-176533
    S1PR5-IN-1

    		LPL Receptor Neurological Disease
    S1PR5-IN-1 (Compound 7a) is a selective and BBB-penetrable S1PR5 inhibitor with an IC50 of 85.4 nM. S1PR5-IN-1 has a superior binding capacity on S1PR5 with Kds of 2.2, 4.6, and 27.6 nM for recombinant human S1PR5 cell membranes, C57BL/6 mouse brain, and human cerebral cortex, respectively. S1PR5-IN-1 can be used for neurodegenerative disorders like multiple sclerosis research .
    S1PR5-IN-1
  • HY-117427
    D5D-IN-326
    1 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-W768347
    Xylitol-13C5

    Xylite-13C5

    		 Isotope-Labeled Compounds Bacterial Autophagy Endogenous Metabolite Atg8/LC3 Atg7 Cancer
    Xylitol- 13C5 (Xylite- 13C5) is the 13C-labeled Xylitol (HY-N0538). Xylitol can be classified as a polyol and sugar alcohol, exhibiting inhibitory activity on cancer cell proliferation. It induces autophagy (Autophagy) and cell death in A549 cells by activating the autophagy signaling pathway, as evidenced by the increased expression of LC3-II and Atg5-Atg12 upon Xylitol treatment. Additionally, Xylitol inhibits acetaldehyde production by Candida species, thereby reducing their carcinogenic potential. In vivo, Xylitol induces alterations in the gut microbiota of mice, which may enhance cholesterol accumulation and upregulate hepatic ChREBP, while also slowing tumor growth in the B16F10 melanoma C57BL/6 mouse model .
    Xylitol-13C5
  • HY-173309
    P53/TLR2 modulator-1

    		MDM-2/p53 Toll-like Receptor (TLR) Apoptosis MyD88 Bcl-2 Family Interleukin Related Cancer
    P53/TLR2 modulator-1 (Compound Z9) is a modulator that targets both the P53 pathway and TLR2 simultaneously, exhibiting anti-radiation activity. P53/TLR2 modulator-1 reduces apoptosis by inhibiting the radiation-induced expression of P53 and Bax. At the same time, it activates the TLR2 pathway, upregulates the expression of downstream proteins MyD88 and P65, and promotes the secretion of cytokines such as IL-6, thus exerting an anti-radiation effect. P53/TLR2 modulator-1 shows significant anti-radiation activity against both AHH-1 cells and HUVECs. It can also increase the survival rate of C57BL/6J mice irradiated with a lethal dose of radiation and reduce the damage to their hematopoietic system, the villous structure of the small intestine, and the spleen caused by radiation. P53/TLR2 modulator-1 can be used in the research of radiation injury-related diseases .
    P53/TLR2 modulator-1
  • HY-D1056A5
    Lipopolysaccharides, from E. coli K-235

    LPS, from Escherichia coli (K-235)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli (Escherichia coli) K-235 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli K-235 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A). Lipopolysaccharides, from E. coli K-235 have a mitogenic effect on C57BL/10ScN spleen cells. Additionally, LPS purified using butanol and deoxycholic acid methods stimulates spleen cells in C57BL/10ScCR and C3H/HeJ mice .
    It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
    Lipopolysaccharides, from E. coli K-235
  • HY-171034
    PQA-18

    		Interleukin Related TNF Receptor PAK Inflammation/Immunology
    PQA-18 is a unique PAK2 inhibitor (IC50: 10 nM). PQA-18 has immunosuppressing effects. PQA-18 suppresses IL2, IL4, IL6, and TNFα. PQA-18 inhibits the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens as well as alleviates dermatitis in mice .
    PQA-18
  • HY-A0032A
    Valganciclovir hydrochloride

    		CMV Infection Inflammation/Immunology Cancer
    Valganciclovir hydrochloride is an orally active antiviral agent. Valganciclovir hydrochloride can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir hydrochloride can be used for the research of Cytomegalovirus .
    Valganciclovir hydrochloride
  • HY-163482
    ELQ-596

    		Parasite Infection
    ELQ-596 is a quinolone derivative, that exhibits antimicrobial activity against several protozoan parasites, including the intraerythrocytic parasites Plasmodium and Babesia. ELQ-596 attenuates babesiosis in immunosuppressed mice .
    ELQ-596
  • HY-163484
    ELQ-650

    		Parasite Infection
    ELQ-650 is a quinolone derivative, that exhibits antimicrobial activity against several protozoan parasites, including the intraerythrocytic parasites Plasmodium and Babesia. ELQ-650 attenuates babesiosis in immunosuppressed mice .
    ELQ-650
  • HY-N6727
    Gliotoxin

    Aspergillin

    		 Apoptosis PKA NF-κB Bacterial Fungal Antibiotic Infection Inflammation/Immunology Cancer
    Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .
    Gliotoxin
  • HY-146215
    IDO1-IN-20

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Hy-146215 is an enzyme that catalyzes the oxidative metabolism of tryptophan. It can immunosuppress tumors in the tumor microenvironment.
    IDO1-IN-20
  • HY-N15180
    Corynantheidine

    (-)-Corynantheidine

    		 Opioid Receptor Neurological Disease
    Corynantheidine ((-)-Corynantheidine) is a mu-opioid receptor (MOR) partial agonist that shows MOR-dependent analgesic effects in mice .
    Corynantheidine
  • HY-137440A
    Firazorexton hydrate

    TAK-994

    		 Orexin Receptor (OX Receptor) ERK Neurological Disease
    Firazorexton hydrate (TAK-994) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton hydrate can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .
    Firazorexton hydrate
  • HY-120872
    AJS1669 free acid

    		Glycosyltransferase Metabolic Disease
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
    AJS1669 free acid
  • HY-A0032AR
    Valganciclovir hydrochloride (Standard)

    		Reference Standards CMV Infection Inflammation/Immunology
    Valganciclovir (hydrochloride) (Standard) is the analytical standard of Valganciclovir (hydrochloride). This product is intended for research and analytical applications. Valganciclovir hydrochloride is an orally active antiviral agent. Valganciclovir hydrochloride can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir hydrochloride can be used for the research of Cytomegalovirus .
    Valganciclovir hydrochloride (Standard)
  • HY-N10346A
    Gluconapin

    		Endogenous Metabolite Cancer
    Gluconapin is a precursor of sulforaphane, a potent anticancer isothiocyanate. Gluconapin reduces the increase in plasma triglycerides induced by corn oil in mice .
    Gluconapin
  • HY-160696
    ORIC-533

    		CD73 Cancer
    ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .
    ORIC-533
  • HY-113878
    12-OAHSA

    		Endogenous Metabolite Metabolic Disease
    12-OAHSA is a component of olive oil. 12-OAHSA has oral activity, and improves glucose homeostasis in insulin resistant obese mice .
    12-OAHSA
  • HY-138842
    DDN

    		Insulin Receptor Akt ERK Metabolic Disease
    DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
    DDN
  • HY-137440
    Firazorexton

    TAK-994 free base

    		 Orexin Receptor (OX Receptor) ERK Neurological Disease
    Firazorexton (TAK-994 free base) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton (TAK-994 free base) can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .
    Firazorexton
  • HY-153617
    FOXO1-IN-3

    		FOXO Metabolic Disease
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
    FOXO1-IN-3
  • HY-162396
    P-gp inhibitor 21

    		P-glycoprotein Cancer
    P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .
    P-gp inhibitor 21
  • HY-126426
    CBHcy

    		DNA Methyltransferase Cardiovascular Disease
    CBHcy is an inhibitor for betaine-homocysteine S-methyltransferase (BGMT), with an IC50 of 0.09 μM. CBHcy upregulates the plasma total homocysteine and causes transient hyperhomocysteinemia in mice model .
    CBHcy
  • HY-P3134
    CPN-267

    		Neuromedin U Receptor (NMUR) Metabolic Disease
    CPN-267 (compound 7b) is a selective neuromedin U receptor 1 (NMUR1) agonist with the EC50 of 0.25 nM. CPN-267 suppresses body weight gain in mice and can be used for study of obesity .
    CPN-267
  • HY-129661
    AH 7959

    		Opioid Receptor Neurological Disease
    AH 7959 is an orally active N-substituted cyclohexyl methyl benzamide compound that has analgesic effects, the oral and subcutaneous ED50 of AH 7959 in mice is greater than 100 mg/kg .
    AH 7959
  • HY-P6053
    KK-103

    		Opioid Receptor Neurological Disease
    KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .
    KK-103
  • HY-P991595
    HB-0017

    		Interleukin Related Inflammation/Immunology
    HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
    HB-0017
  • HY-N10445
    Maydispenoid A

    		CD28 CD3 Inflammation/Immunology
    Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .
    Maydispenoid A
  • HY-N10446
    Maydispenoid B

    		CD28 CD3 Inflammation/Immunology
    Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .
    Maydispenoid B
  • HY-168365
    (±)-Pellotine hydrochloride

    		Drug Isomer Neurological Disease
    (±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice .
    (±)-Pellotine hydrochloride
  • HY-169421
    Nav1.7-IN-18

    		Sodium Channel Cancer
    Nav1.7-IN-18 (Compound 31) is a Nav1.7 inhibitor with a Ki value of 4.9 nM and an IC50 of 13 nM, showing analgesic effects in transgenic mice with inherited erythromelalgia (IEM) .
    Nav1.7-IN-18
  • HY-N15182
    4-Trehalosamine

    		Bacterial Drug Derivative Infection
    4-Trehalosamine is a derivative of trehalose with weak antibacterial activity. 4-Trehalosamine shows no toxic effects when injected intravenously into mice at a dose of 625 mg/kg .
    4-Trehalosamine
  • HY-110197
    6bK TFA
    1 Publications Verification

    		 Insulin Receptor Metabolic Disease
    6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice .
    6bK TFA
  • HY-162683
    (S)-PHA533533

    		CDK Neurological Disease Cancer
    (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice .
    (S)-PHA533533
  • HY-P1434
    [Pro3]-GIP (mouse)

    		Insulin Receptor Metabolic Disease
    [Pro3]-GIP (mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .
    [Pro3]-GIP (mouse)
  • HY-159972
    PKR1 antagonist 1

    		G Protein-coupled Receptor Kinase (GRK) Neurological Disease
    PKR1 antagonist 1 (PC1) is a potent PKR1 antagonist. PKR1 antagonist 1 reduces hyperalgesia and allodynia in SNI mice .
    PKR1 antagonist 1
  • HY-125721
    Tetranactin

    		Fungal Bacterial Antibiotic Infection
    Tetranactin is an orally active antibiotic that has insecticidal properties and can inhibit the growth of Gram-positive bacteria and plant pathogenic fungal in vitro. Tetranactin LD50 for intraperitoneal injection in mice is greater than 300 mg/kg, and the LD50 is greater than 15,000 mg/kg .
    Tetranactin
  • HY-129762
    Yoshi-864

    NSC-102627

    		 DNA/RNA Synthesis Cancer
    Yoshi-864 (NSC-102627) is an alkylsulfonate DNA crosslinker with anticancer activity. Yoshi-864 extends markedly the survival times of mice bearing L1210 leukemia or Ehrlich ascites carcinoma. Yoshi-864 also has a persistent reduction in ability to synthesize DNA in tumor cells from mice bearing the Ehrlich tumor .
    Yoshi-864
  • HY-131334
    AMPK activator 4

    		AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
    AMPK activator 4
  • HY-174381
    BChE-IN-41

    		Cholinesterase (ChE) Amyloid-β Tau Protein Neurological Disease
    BChE-IN-41 is a highly selective Butyrylcholinesterase (BChE) inhibitor (IC50 =12 nM, Ki = 6.6 nM). BChE-IN-41 has high brain penetration with a brain-to-plasma ratio of 9.0. BChE-IN-41 has pro-cognitive effects on mice with AD-like symptoms induced by Scopolamine (HY-N0296) and Aβ1-42 .
    BChE-IN-41

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: